Switch to a raltegravir-based antiretroviral regimen in people with HIV and non-alcoholic fatty liver disease: A randomized controlled trial.
Mohamed ShengirBertrand LeboucheWesal ElgretliSahar SaeedAgnihotram V RamanakumarAndreas GiannakisAlexandra De PokomandyJoseph CoxCecilia T CostiniukJean-Pierre RoutyMarina B KleinGiada SebastianiPublished in: HIV medicine (2023)
Switching to a raltegravir-based regimen improved aspartate aminotransferase but seemed to have no effect on NAFLD, body weight, and lipids compared with remaining on any other ART.